Evaluating a new dengue vaccine in healthy adults.
Official title: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE-RANGING STUDY TO COMPARE THE SAFETY AND EFFICACY OF 3 DOSE LEVELS OF AV-1 IN HEALTHY ADULTS CHALLENGED WITH A CONTROLLED HUMAN INFECTION S
Funded at Johns Hopkins University · NIH-11076168 · Data updated 2026-11-12
This study is testing a new dengue vaccine called AV-1 to see how safe and effective it is for healthy adults, and participants will either get the vaccine or a placebo before being exposed to the dengue virus to help find the best dose for future use.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | August 23, 2023 |
| Project end | July 22, 2025 |
| Funding year | 2024 |
| Award (this year) | $321,765 |
| NIH project number | 75N93019D00031-P00001-759302300004-1 |
| Project ID | NIH-11076168 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are healthy adults who are willing to participate in a clinical trial and meet specific eligibility criteria.
✕Less likely to help
Patients with a history of severe allergic reactions to vaccines or those with compromised immune systems may not benefit from this research.
What this research studies
This research investigates the safety and effectiveness of a new dengue vaccine candidate called AV-1 in healthy adults. Participants will be randomly assigned to receive either the vaccine at different dose levels or a placebo, and will then be exposed to a controlled dengue virus infection. The study aims to assess how well the vaccine works and its safety profile through careful monitoring and analysis of participants' responses. This approach helps determine the best dose for future use in larger populations.
Why it matters
Potential benefit: If successful, this research could lead to a safe and effective vaccine against dengue fever, potentially reducing the incidence of this disease.
How similar studies have gone: Previous research has shown promise in developing vaccines for dengue, indicating that this approach has potential based on earlier successes.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Durbin, Anna Palmer — Johns Hopkins University
- Study coordinator: Durbin, Anna Palmer
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.